Sponsors (5)
The bill increases veterans' timely access to life‑saving opioid antagonists (likely reducing overdoses and some health costs) while creating modest new VA program costs, potential cost‑shifts, and implementation/liability challenges for the VA.
Veterans: can obtain opioid antagonists (e.g., naloxone) from the VA without a prescription, increasing timely access to life‑saving overdose reversal medication.
Veterans and the VA health system: easier, non‑prescription access to opioid antagonists is likely to reduce overdose events and emergency care needs and may lower downstream health care costs.
Veterans and taxpayers: furnishing opioid antagonists without a prescription will increase VA program costs and may require new funding or reallocation of VA resources.
Veterans and VA budgets: removing language in the copayment subsection could reduce cost‑sharing for some veterans and shift costs to other parts of the VA budget or to taxpayers.
VA staff and facilities: without clear implementation guidance, distributing opioid antagonists without prescriptions could create liability, training, storage, and administration burdens or risks for federal employees and VA sites.
Based on analysis of 2 sections of legislative text.
Directs the VA to furnish an opioid antagonist to a veteran without a prescription and removes part of a copayment provision.
Directs the Department of Veterans Affairs to provide an opioid antagonist (for example, naloxone) to a veteran without requiring a prescription. It also removes a portion of existing statutory language tied to copayment rules, which alters how a particular copayment clause reads and may affect cost-sharing for affected veterans.
Introduced November 10, 2025 by Herbert C. Conaway · Last progress November 10, 2025